Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ginfort is a proprietary **oral botanical ginger extract** developed by Olene Life Sciences and exclusively licensed to DolCas Biotech. It is a patented, solvent-free supercritical CO2 extract of *Zingiber officinale* oleoresin standardized to 26% gingeroids, principally gingerols and shogaols, and formulated with proprietary Aqueosome technology to improve solubility and bioavailability of these lipophilic constituents. Although not a pharmaceutical drug, Ginfort has been clinically studied as a small-molecule nutraceutical for functional dyspepsia and primary dysmenorrhea, where it has shown symptom reduction at 200 mg twice daily. Its proposed mechanism includes carminative and prokinetic effects that reduce gas and improve synchronized gastrointestinal peristalsis, along with suppression of cyclooxygenase-2 driven prostaglandin formation that may contribute to analgesic and anti-inflammatory effects in menstrual cramping and upper GI discomfort.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ginfort.